PRPROCEPT BioRobotics PRCT · NASDAQ
$20.03 +9.63% (+$1.76)
- Market cap
- $1.14B
- Enterprise value
- $989.7M
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 3.4x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -27.4%
- Gross margin
- 63.7%
- Net margin
- -32.5%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 0.92
- Free float
- 96.0%
About the company
PROCEPT BioRobotics Corporation is a U.S.-based healthcare company specializing in the development and commercialization of advanced robotic devices for urology. The company is particularly known for its robotic system Aquablation®, which uses water energy to precisely remove prostate tissue in patients suffering from benign prostatic hyperplasia (BPH). This innovative approach enables minimally invasive procedures with high precision, improving treatment outcomes and recovery times for patients. PROCEPT BioRobotics focuses on enhancing the efficiency and safety of urological procedures.
Sector
Healthcare
Industry
Medical - Devices
CEO
Larry L. Wood
Employees
888
Headquarters
San Jose
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number